Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

This study has been completed.
Information provided by (Responsible Party):
CASI Pharmaceuticals, Inc. Identifier:
First received: April 11, 2008
Last updated: January 26, 2016
Last verified: January 2016